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Adenocarcinoma of the pancreas remains one of the leading causes of cancer death in the United States, ranking fourth. 1 The median survival of patients with resectable tumor is 10 to 20 months, whereas the rates for patients with locally aggressive and metastatic disease are 6 to 10 months and 3 to 6 months, respectively. 2 The abysmal outcome of this tumor is shown in the cancer annual statistics in which the mortality rate, 31,270 per year, approximates the incidence rate, 31,860 per year. 1 Several reasons have been given to explain this poor outcome of pancreatic tumor, including the anatomic relation of the pancreas to the retroperitoneal space, liver, stomach, duodenum, and great vessels and the pancreas intrinsic vasculature, bidirectional lymphatics, and innervations. 3 These factors, besides the innately aggressive behavior of the tumor, complicate the clinical outcome of pancreatic carcinoma so much that at the time of diagnosis, only 20% of tumors are deemed resectable with the rest being equally divided between locally aggressive (40%) and metastatic (40%). 4 Despite these statistics, diagnostic and treatment options have evolved remarkably during the last decade. The emergence of centers of excellence for pancreatic cancer care and the new generation of chemotherapeutic agents has prompted optimism for improving survival by appreciable numbers. [4] [5] [6] [7] [8] On the diagnostic front, the cytologic features for pancreatic adenocarcinoma have been redefined, resulting in a noticeable improvement in fine-needle aspiration (FNA) diagnostic performance. [9] [10] [11] [12] Recently, endoscopic ultrasound-guided (EUS) FNA has replaced computed tomography (CT)-guided FNA and needle biopsy as the method of choice for the diagnosis of pancreatic adenocarcinoma. [13] [14] [15] [16] [17] [18] [19] [20] Increasingly, cytologic material obtained through this technique has become the only tissue sample available from pancreatic adenocarcinoma, principally in the 80% or so unresectable tumors. It is of considerable interest, therefore, to know whether cytologic features could offer an additional prognostic indicator for pancreatic adenocarcinoma. The objectives of this study were to devise a cytologic grading system applicable to air-dried rapid Romanowsky-stained smears of EUS FNA samples of pancreatic adenocarcinoma and to determine whether this grading system predicts the extent of the tumor (stage) and survival of patients with pancreatic adenocarcinoma.
Materials and Methods

Patients
The study included 116 consecutive patients with pancreatic adenocarcinoma diagnosed within the University of Alabama at Birmingham Health System during the period July 2000 to November 2002 and followed up until September 2003. None of the patients had previously received pancreatic cancer-specific treatment. Patients with the diagnosis of cystic pancreatic lesions or neuroendocrine, bile duct, duodenal, or ampullar carcinomas and patients with equivocal cytologic diagnosis were excluded from the study. The University of Alabama at Birmingham Institutional Review Board approved the study.
EUS FNA
One attending gastroenterologist (M.A.E.) performed all EUS staging using a radial echoendoscope (model GF-UM130; Olympus, Melville, NY) following a standard protocol. 13, 14 A curvilinear echoendoscope (model UC-30P; Olympus) and a 22-gauge needle (Echotip; WilsonCook, Winston Salem, NC) were used to obtain cytologic material.
Air-dried smears were stained with rapid Romanowsky (Diff-Quik, Baxter, McGaw Park, IL) and reviewed by a cytopathologist (I.A.E., D.C.C., D.J., R.C., and N.C.J.) to ensure specimen adequacy. The cytologic diagnoses were classified as malignant or benign based on well-established cytologic criteria. 9, 10, 13, 21 The minimal features required for carcinoma include anisonucleosis, nuclear crowding and overlapping ("drunken honeycomb"), nuclear enlargement (>2.5 times the size of an RBC area), nuclear outline irregularity, and a few singly scattered malignant cells in the background. The final diagnosis of pancreatic carcinoma was confirmed by histologic evidence or by imaging and/or clinical follow-up. Lesions were considered benign if there was spontaneous resolution or no progression during the follow-up period.
Cytologic Grading
Without knowledge of the stage and clinical outcome, 1 pathologist (I.A.E.) reevaluated all smears from all patients ranging from 5 to 27 slides per patient. Areas showing the worst differentiation were scored for nuclear pleomorphism, mucin production, cohesion of cell groups, and the presence of single cells. These features were selected to reflect the World Health Organization (WHO) histologic grading system for pancreatic adenocarcinoma. 22, 23 The latter 2 features were considered the equivalent of architectural and glandular differentiation in the WHO grading system. Mucin was scored only when present in close association with malignant cells and away from benign gastric or duodenal epithelium. The presence of necrosis and bizarre cells was added to this grading system because these factors were presumed to be associated with poor differentiation. The presence of neutrophils and proteinaceous exudates was noted but not considered tumor necrosis. Bizarre cells were defined as epithelial cells with large nuclei (>6 times the area of an RBC) with noticeable membrane irregularity and frequent multilobation or multinucleation. Evaluation of mitosis was dropped from the cytologic grading system because we found it difficult, time-consuming, and nonuniform among a set of slides from 1 patient.
With a possible total score range of 0 (cases that scored 0 for each criterion) to 8 (cases that scored the highest mark for each criterion), the cytologic grade was determined. A total score of 0 or 1 was defined as low grade and of 2 through 8 as high grade ❚Table 1❚ and ❚Image 1❚.
Reproducibility
Two cytopathologists (I.A.E. and D.C.C.) independently scored smears from 71 consecutive cases of the study population. The κ statistic was used to determine the reproducibility of the cytologic grade. When biopsy or surgical material was available, the agreement between cytologic grade and histologic grade as stated in the surgical pathology report was determined by using the κ statistic.
Staging and Treatment
Based on chest and abdomen CT scans, EUS, and operative findings, tumors were staged using the TNM (International Union Against Cancer) system. If there was evidence of metastasis (stage IV), patients were treated with systemic chemotherapy and/or radiation. Surgical exploration was performed when tumors were judged to be resectable (no arterial involvement and a patent portal vein based on CT and EUS findings). Palliative shunting or some form of pancreatectomy was performed based on operative findings. Because this was a retrospective study, patients might have received multiple types of cancer-specific treatment, ie, resection, radiation, and/or chemotherapy.
Follow-up
We reviewed the medical records, imaging reports, and operative notes and, if appropriate, called the referring physicians and/or family members about the patient's clinical course and outcome.
Data Collection and Analysis
Clinical and pathologic data were extracted from prospectively maintained databases. Information obtained for analysis of survival includes patient demographics, tumor characteristics, and treatment modalities.
Categorical data are given as proportions or frequencies and compared by using the χ 2 test, whereas continuous data are given as mean ± SD and compared by using the Student t test. To search for an association of cytologic grade with demographics, stage, or treatment option, we used a binary logistic regression, the forward maximal likelihood method, with grade (high vs low) as the dependent variable. By using Kaplan-Meier methods, survival analysis was calculated from the date of EUS FNA diagnosis until the date of death or until the date of loss to follow-up. Levels of survival predictive factors were compared by using the log-rank test, and data are given as the median value with 95% confidence intervals. To control for confounding risk factors, Cox proportional hazards regression analysis was performed using the forward maximal likelihood method. To define high and low cytologic grades, we used different cutoff values of total cytologic scores, and the best total scores that predicted survival (0 or 1 for low grade; 2 through 8 for high grade) were chosen for the final model.
Results were considered statistically significant when P was less than .05. Statistical analysis was performed using the SPSS statistical package (SPSS for Windows, version 10.1, SPSS, Chicago, IL).
Results
Patient Characteristics
The median age was 65 years (range, 41-86 years); 56.0% of patients were men and 80.2% were white. All patients had the classic pancreatic cancer symptoms of jaundice, abdominal pain, and/or weight loss. Based on imaging studies, all patients had a solid pancreatic mass and 14 (12.1%) had evidence of concurrent chronic pancreatitis. The mass was located in the head of the pancreas in 70 patients (60.3%), in the uncinate in 19 (16.3%), in the body in 24 (20.7%), and in the tail in 3 (2.6%). Tumor size measured more than 30 mm in 59 patients (50.9%) on EUS imaging. At diagnosis, 12 patients (10.3%) had stage I disease, 24 (20.7%) had stage II, 36 (31.0%) had stage III, and 43 (37.1%) had stage IV. Staging information was missing for 1 patient.
Developing a Cytologic Grading System
On cytologic examination, discohesive 3-dimensional groups were found in 69 cases (59.5%), background mucus was absent in 73 cases (62.9%), and necrosis was identified in 46 cases (39.7%). Numerous single cells were seen in 10 cases (8.6%), a moderate number in 44 cases (37.9%), and a few in 62 cases (53.4%). Marked pleomorphism was found in 31 cases (26.7%), moderate pleomorphism in 42 cases (36.2%), and mild nuclear pleomorphism in 43 cases (37.1%). Bizarre cells were seen in 44 cases (37.9%). These cytologic features were not mutually exclusive: 5 cases (4.3%) were scored positive for all features considered markers of poor differentiation, and 22 cases (19%) were scored negative for all of these features ❚Table 2❚.
Because none of the cytologic features alone predicted survival, we created a total cytologic score for each case. Through testing of different cutoff values of the total cytologic score, we found that a total score of 2 or more independently predicted poor survival. By using this grading system (0 or 1 for low-grade tumors and 2 through 8 for high-grade tumors), we classified 42 tumors (36.2%) as low grade and 74 (63.8%) as high grade. as high grade, and the other graded 20 cases as low grade and 51 as high grade. They agreed on the grading of 56 (79%) cases (κ = 0.52; P < .001).
Reproducibility
Only 13 cases had a histopathologic diagnosis, 3 well-differentiated, 8 moderately differentiated, and 2 poorly differentiated tumors. Cytologic examination revealed that 7 of these were graded as high-and 6 as low-grade tumors. There was agreement between cytologic and histologic diagnoses only when the histologic features were graded in 2 grades, high and low, with moderately differentiated tumors considered highgrade tumors (κ = 0.58; P < .05).
Patient and Tumor Characteristics Are Balanced Between Low-and High-Grade Tumor Groups
There was no significant difference in age, sex, or racial distribution between high-and low-grade tumors ❚Table 3❚. There was no significant difference between maximum diameters of low-vs high-grade tumors. In addition, there was no association between tumor grade and nodal status, presence of metastasis, or presence of vascular invasion. With univariate and multiple logistic regression, there was no association between cytologic grade and TNM staging, entered in the model as 4 groups (stages I, II, III, and IV) or as 2 groups, resectable (stages I and II) vs nonresectable (stages III and IV) or as nonmetastatic (stages I-III) vs metastatic (stage IV) ( Table 3) .
Patients with low-cytologic-grade tumors were more likely to receive cancer-specific treatment (Table 3) : 68 patients received cancer-specific treatment (surgical resection, chemotherapy, and/or radiation), whereas 48 patients did not; 13 patients underwent tumor resection (standard Whipple procedure or other forms of pancreatectomy); there was no difference between the numbers of low-vs high-grade tumors that were resected. Of the 13 patients, 5 received combined Anatomic Pathology / ORIGINAL ARTICLE E F G H E, Cell groups falling apart (score, 1), single cells (score, 1), necrosis (score, 0), nuclear pleomorphism (score, 2), bizarre cells absent (score, 0), mucus absent (score, 1). F, Bizarre cells (score, 1). G, Cell group falling apart (score, 2) and nuclear pleomorphism (score, 2). H, An acinar structure with low nuclear score (0) to the left and high nuclear score (1-2) to the right. Note the bizarre cell at 1 o'clock. In the background, a few cells show a high nuclear score (2) . This image shows the heterogeneity of grading within the same case (A-H, rapid Romanowsky, ×400). 
Cytologic Grade Independently Predicts Survival
During the study period (29 months), 21 patients (50%) with low-grade carcinoma died compared with 44 patients (59%) with high-grade carcinoma. As shown in ❚Figure 1❚, for the 116 patients with pancreatic carcinoma, the Kaplan-Meier estimate of 6-month survival was 76% (SE, 7%) for patients with low-grade tumors vs 50% (SE, 6%) for patients with high-grade tumors. The 1-year survival was 44% (SE, 10%) for patients with low-grade tumors compared with 31% (SE, 7%) for patients with high-grade tumors. The log-rank test showed statistically significant differences in survival of patients with low-vs high-grade tumors. The median survival for patients with low-grade tumors was 1 year compared with 6 months for patients with high-grade tumors (Figure 1) . One telling feature of the aggressiveness of pancreatic cancer was the steep nature of the survival curve regardless of the grade. By 18 months, only 6 patients remained alive, 4 in the lowgrade group (who all died by the end of the study) and 2 in the high-grade group (one died and the other was lost to followup at the end of the study). As expected, nonmetastatic stages and cancer-specific treatment were significant predictors of survival. The median survival of patients who were treated for nonmetastatic tumor was 11.97 months (95% CI, 5.91-18.20), whereas that of untreated patients with metastatic disease was 2.5 months (95% CI, 0.07-4.93). Cytologic grade remained a significant predictor of survival when we stratified patients by cytologic grade independent of all other potential predictors except treatment ❚Table 4❚. Despite more patients with low-grade tumors receiving cancer-specific treatment, treatment had no effect on their survival (median survival, 11.97 months for treated and untreated patients) compared with its effect on patients with high-grade lesions. The median survival was prolonged by 12 months in the latter group (median survival, 17 .43 months in the treated group compared with 2.5 months for the untreated group) ( CI, 95% confidence interval; PP, log-rank test pooled P value after adjusting for stratum; SP, log-rank test P value after adjusting for stratum. * Groups too small for valid statistical analysis. † Information missing for 2 high-grade cases.
This effect was most pronounced in patients with unresectable tumors but not in patients with resectable tumors (Table 4) . All other factors, including age, mass location, placement of stent, presence of concomitant chronic pancreatitis, race, and sex did not predict survival of patients with pancreatic cancer in this study.
Discussion
During the last 10 years or so, the improvement in sensitivity and specificity of FNA in the diagnosis of pancreatic cancer has been largely attributable to better defining the criteria that discriminate between well-differentiated adenocarcinoma and chronic pancreatitis. [9] [10] [11] [12] Although 3 grades of pancreatic adenocarcinoma are well recognized in the cytologic literature, the features that distinguish well-differentiated carcinoma from higher-grade carcinoma (moderately and poorly differentiated carcinoma), to our knowledge, have never been correlated with clinical outcome. In the present study, we developed a cytologic grading system that independently predicted survival of patients with pancreatic carcinoma.
As expected, tumors of patients who showed better survival (low-grade tumors) were formed of relatively cohesive irregular clusters (drunken honeycomb), lacked necrosis and pleomorphism, and had noticeable background mucin and few single cells. On a scale of 0 to 4, Robins et al 10 graded the presence of mucus, necrosis, nuclear pleomorphism, presence of giant cells, and presence of single cells on CT-guided FNA of pancreatic adenocarcinoma. If we consider their score of 2+ or greater as equivalent to our score of 1 for the presence of mucus, necrosis, giant cells, and discohesive cell groups and the absence of mucus, the frequency for each feature is not significantly different from the frequency in the present study. The frequencies for nuclear grade and single cell scores also are not significantly different from the frequencies in the present study, provided we consider their score of 0 to 1+ equivalent to our 0 score, 2 or 3+ to our 1 score, and 4+ to our 2 score. Unfortunately, Robins et al 10 did not try to distinguish well-differentiated from highergrade tumors because their major quest was to discriminate between well-differentiated carcinoma and chronic pancreatitis.
The frequency of low-grade and high-grade carcinoma, 36.2% and 63.7%, respectively, in the present study is higher than most frequencies reported in studies based on histologic grading systems. 6, [22] [23] [24] [25] [26] [27] [28] Because we graded tumors on a 2-tiered system, the middle category in a 3-tiered system, which ranges from 51% to 73%, 6,22-28 must have been divided in the present study between low and high grade by a factor of approximately 1:2 in favor of high grade. Kloppel et al 22 recognized this difficulty in distinguishing moderately from poorly differentiated carcinoma and contemplated the use of a 2-rather than 3-tiered system.
Because of the improved survival in patients with lowgrade tumors, one might speculate that this group included misdiagnosed cases of focal chronic pancreatitis 29, 30 or mucinous cystic neoplasm. Several points, however, argue against such an assumption. First, our low-grade tumors showed the minimal cytologic changes needed to diagnose carcinoma that had been proven by other investigators to be characteristic features of well-differentiated adenocarcinoma. Imaging studies and gross inspection of aspirated material excluded cystic neoplasm. Second, all patients who underwent resection showed histologic evidence of the disease, and in patients with unresectable tumors, clinical, radiologic, and disease progression factors confirmed the diagnosis. Finally, the most likely "over-called" cases of chronic pancreatitis would be cases with stage I and low-grade tumor (2 cases; Table 3 ). Both patients were older than 70 years and had a mass in the pancreas and weight loss, and neither had evidence of chronic pancreatitis on ultrasound examination. Both patients died during the course of this disease, one after surgery allowing confirmation of the diagnosis of pancreatic cancer histologically.
Grade as a predictor of tumor behavior has been used extensively in clinical practice for tumors of various organs such as those of the prostate and endometrium, in which it had a major impact on clinical decision making and therapeutic options. 2 From experimental, epidemiologic, and clinical data, there is a large body of evidence demonstrating the association between pancreatic tumor grade and its behavior. Twenty years ago, using xenograft models in immunodeficient animals, Kloppel et al 22 showed that the tumor doubling time of poorly differentiated carcinoma was shorter than that of moderately differentiated adenocarcinoma, which was in turn shorter than that of well-differentiated carcinoma. Conversely, Coen et al 31 showed that fast-growing pancreatic adenocarcinoma cell lines tended to have larger "lesser" nuclear diameters, higher optical densities, and longer perimeters. These experiments strongly linked tumor grade to tumor growth kinetics in vivo and in vitro.
Two recent large studies confirmed the original findings of Kloppel et al 22 that patients with low-grade adenocarcinoma have longer survival than those with high-grade adenocarcinoma. First, the European Study Group for Pancreatic Cancer-1 with 541 subjects showed that tumor grade, nodal status, maximum tumor diameter, and age were independent predictors of survival. 25 The other study was a large population-based survey linked to the Surveillance, Epidemiology, and End Results registries in which Lim et al 6 found the following factors to be associated independently with poor survival of patients with pancreatic adenocarcinoma: moderately or poorly differentiated grade, African American race, treatment in a nonteaching hospital, lack of adjuvant chemoradiation therapy, tumor more than 2 cm, "positive" lymph nodes, and low socioeconomic status. Except for socioeconomic data and hospital setting, we tested all of the potential confounding factors identified by Lim et al 6 in our regression models; cytologic grade, together with stage and treatment, remained independent predictors of survival.
There are few studies that showed no association between tumor differentiation and survival. 28, 32 As suggested by Luttges et al, 23 the frequency distribution of tumor grades in these studies was significantly different from most of the studies that showed tumor grade as a good predictor of survival. For example, 3% of cases involved low-grade tumors in the study by Yeo et al 28 ; Sohn et al 33 more recently reported a larger case series with 6% low-grade tumors. Unlike the study by Yeo et al, 28 the more recent study found tumor grade to be a significant predictor of survival. 33 In the study by Tannapfel et al, 32 there was a large preponderance of moderately differentiated tumors (75%), and low and high grades were underrepresented. Patient selection, heterogeneity of treatment, heterogeneity of pancreatic adenocarcinoma, and lack of reproducibility of tumor grading systems also might explain the differences between these studies and ours.
An unexpected finding in our study was that despite the lack of association between tumor grade and the extent of the disease (stage), tumor grade predicted survival. This is contrary to the findings of Kloppel et al 22 and to the general notion that a high-grade lesion leads to high-stage disease that leads to poor survival. 34 In our study, grade and stage were independent predictors of survival when the stages were entered in Cox regression models as groups-metastatic (stage IV) vs nonmetastatic (stages I-III)-but not when entered as individual stages. Grade predicted survival in patients with unresectable but not with resectable tumors (Table 4) . Perhaps the survival benefits of surgery in those with resectable tumors overcame any adverse effect of having a high-grade tumor. The small number of patients with stage I and low-grade tumors precludes meaningful statistical analysis in the latter case. A larger study might resolve this issue of statistical power.
As we would believe intuitively, patients with nonmetastatic low-grade tumors survived longer (median survival, 13.5 months; 95% CI, 9.89-17.11) than patients with metastatic high-grade tumors (median survival, 5.97 months; 95% CI, 3.53-8.40). Care should be exercised before drawing strong conclusions about grade predicting survival without assessing the interaction of treatment. Because patients with low-grade tumors were likely to receive treatment, one may tend to think that the improvement of survival was merely a confounding effect of treatment. Cox regression analysis was performed to control for that effect, but more important, we did not find treatment to have any effect on patients with lowgrade tumor who received it; rather, treatment increased the median survival of patients with high-grade lesions by almost 15 months (17.43 from 2.5 months) ( Table 4 ). This is hardly surprising because in many other organ sites, high-grade tumors generally are more responsive to chemotherapy and radiation therapy than low-grade tumors. If this finding is confirmed further by a large prospective study, it will strongly argue for the use of cytologic grade for selecting patients with disease likely to be more responsive to therapy.
Besides the relatively small number of enrolled subjects, some additional limitations of this study are worth highlighting: First, survival was estimated from the time of EUS FNA rather than from the time of onset of the disease. Because of the occult nature of pancreatic adenocarcinoma and referral patterns from one institution to another, there often is a long delay between onset of symptom and diagnosis. 35 However, because patients with low-grade tumors generally are examined late compared with those with high-grade disease, 22 this delay in diagnosis is more likely to artificially shorten the estimated survival for patients with low-rather than high-grade tumors. 22 Therefore, the observed effect of tumor grade on survival probably would have been higher had we measured survival from the onset of symptoms.
Second, we assumed all deaths in this study to be due to pancreatic carcinoma. This probably is true because the majority of patients with pancreatic cancer die relatively rapidly of this disease. 25 We cannot exclude other causes of death, particularly within this age group, and we have no evidence to believe that patients remaining in the study or patients being lost to follow-up were at different risk of pancreatic cancer outcomes.
Where does this grading system fit in the current management decision tree of pancreatic carcinoma? We believe tumor grade should be considered in selecting for ever-evolving managerial and therapeutic options, especially when one sees the dramatic effect of therapy in high-grade lesions compared with low-grade lesions. The modest reproducibility seen in this study is slightly better than reproducibility of histologic grading. 36 Refining the cytologic criteria and a larger multiinstitutional study might further strengthen our claim, the ultimate test of which will be its direct impact on clinical decision making and patient outcome.
